相关实验视频

Updated: May 15, 2025

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells

Published on: June 5, 2020

通过REV-ERBα修饰剂调节循环胺诱导的肝毒性

Jinyi Wang¹, Jialu Cui¹, Tingying Hao²

¹Department of Public Health and Preventive Medicine, School of Medicine, Jinan University, Guangzhou, China.

Expert opinion on drug metabolism & toxicology

|April 11, 2025

概括

REV-ERBα激动剂,SR9009和Berberine通过调节CYP2B10来降低循环胺 (CPA) 诱导的肝毒性. 这一发现为提高CPA有效性和减少其副作用提供了新的目标.

科学领域:

药理学和毒理学药理学和毒理学
肝病学肝病学是一种肝病学.
药物新陈代谢药物新陈代谢

背景情况:

环胺 (CPA) 是一种重要的抗瘤药物,但由于严重的肝毒性,其临床使用受到限制.
缓解CPA诱导的肝损伤是癌症治疗中的一个重大挑战.

研究的目的:

研究REV-ERBα在CPA引起的肝毒性中的作用.
评估REV-ERBα激动剂 (SR9009和Berberine) 对CPA诱导的肝损伤的保护作用.

主要方法:

在野生型和REV-ERBα淘汰赛小鼠中,使用肝酶 (ALT,AST) 和细胞病理学评估肝毒性.
分析了CYP2B10表达和CPA的药理动力学.
在CPA给药之前,小鼠先用SR9009或Berberine进行预治疗.
在Hepa-1c1c7细胞中验证了SR9009和Berberine对CYP2B10和Bmal1的影响.

主要成果:

REV-ERBα通过影响CYP2B10表达和CPA药理动力学来负面调节CPA诱导的肝毒性.
施用SR9009和Berberine增加了REV-ERBα的表达,并减轻了CPA诱导的肝损伤.
这两种激动剂都在体内和体外减少了CYP2B10和Bmal1的表达.

结论:

REV-ERBα激动剂通过CYP2B10调节有效减轻环胺的肝毒性.
REV-ERBα代表了一种新的治疗点,用于减轻CPA诱导的肝毒性并提高治疗结果.

关键词:

柏柏林蛋白是一种柏柏林蛋白.在CYP2B10中.这就是REV-ERBα.在SR9009中,我们得到了SR9009.环酸胺的使用方法毒性的毒性毒性的毒性

更多相关视频

Reverse Yeast Two-hybrid System to Identify Mammalian Nuclear Receptor Residues that Interact with Ligands and/or Antagonists

Reverse Yeast Two-hybrid System to Identify Mammalian Nuclear Receptor Residues that Interact with Ligands and/or Antagonists

Published on: November 15, 2013

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

相关概念视频

Hepatic Drug Excretion: Enterohepatic Cycling

Hepatic Drug Excretion: Enterohepatic Cycling

Enterohepatic cycling involves the active secretion of drugs and their metabolites into the bile via transporters in the canalicular membrane of hepatocytes. This secretion is an integral part of the digestive process, releasing these substances into the gastrointestinal (GI) tract.
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...

Transducer Mechanism: Nuclear Receptors

Transducer Mechanism: Nuclear Receptors

Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:

Receptor Downregulation in MVBs

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...

Positive Regulator Molecules

Positive Regulator Molecules

To consistently produce healthy cells, the cell cycle—the process that generates daughter cells—must be precisely regulated.

Regulation of Metabolism

Regulation of Metabolism

Cellular needs and conditions vary from cell to cell and change within individual cells over time. For example, the required enzymes and energetic demands of stomach cells are different from those of fat storage cells, skin cells, blood cells, and nerve cells. Furthermore, a digestive cell works much harder to process and break down nutrients during the time that closely follows a meal compared with many hours after a meal. As these cellular demands and conditions vary, so do the amounts and...

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...